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Varicella zoster virus (VZV) causes two distinct viral 
syndromes. VZV infection is a common and usually benign 
childhood infection, manifesting as chickenpox. Herpes zoster 
ophthalmicus (HZO) is a potentially devastating visual disease 
with variable presentation caused by the re-activation of a 
latent infection of the trigeminal ganglion by the VZV.
The most common causes of re-activation of VZV are 
decreased cell-mediated immunity related to age, malignancies, 
chemo- or radiotherapy, HIV infection, and the use of 
immunosuppressive drugs.1 The characteristic vesicular 
cutaneous involvement in the area supplied by the ophthalmic 
division of the trigeminal nerve with respect to the horizontal 
midline is usually the first clinical sign and is often preceded 
by pain in this area caused by viral replication in the ganglion.
Hutchinson’s sign results from the involvement of the skin 
and/or nasal mucosa of the tip of the nose on the ipsilateral 
side of the HZO infection. This involvement of the external 
nasal nerve (the terminal branch of the nasociliary branch of 
the ophthalmic division of the trigeminal nerve) implies a high 
risk of involvement of the earlier ciliary branches supplying 
intra-ocular structures. This relationship between involvement 
of the external nasal nerve and increased likeliness of intra-
ocular involvement was first described by John Hutchinson in 
1865.2
HZO is much more common in immunocompromised 
patients3,4 and especially the HIV-infected population. The 
risk of HZO is up to 15 times higher in HIV-positive than 
HIV-negative patients.5,6 One study6 found the incidence of 
HZO in the HIV-positive population to be around 3.2 per 
100 patient-years of follow-up, which was almost 10 times 
more than the 3.4 per 1 000 patient-years of follow-up in the 
general population. The incidence of HZO in HIV cases has 
not changed significantly since the advent of highly active 
antiretroviral therapy (HAART).7
The most common vision-affecting complications of HZO 
are corneal opacities due to scarring, neovascularisation, 
neurotrophic or secondarily infected ulcers, the sequelae 
of uveitis (i.e. cataract and glaucoma), necrotising retinitis, 
posterior vascular occlusions and optic neuritis.8 The risk of 
ocular complications of HZO is 2 - 3 times higher in the HIV-
infected population than in the general population; however, 
the complication rate has declined slightly since the advent of 
HAART.9
HZO has been described as one of the presenting signs of 
HIV disease.10 It is a powerful predictor of HIV positivity, 
especially in black Africans, with figures of between 50% 
and 95%.4,10,11 No studies were found in the English literature 
on the predictive value of Hutchinson’s sign for intra-ocular 
involvement in the HIV-positive population. However, when 
both the infratrochlear and the external nasal nerve (not 
Hutchinson’s sign) were involved, 100% of patients developed 
intra-ocular involvement.12
The effect of CD4 count on HZO is not fully understood. 
Some studies demonstrated no increased incidence of HZO 
with duration of HIV and presumably declining CD4 count.7,13-16 
It has been suggested that HZO occurs in patients with 
moderate degrees of immunodeficiency, and much less so in 
patients with profound immunodeficiency,7,13,16,17 which would 
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Background. A positive Hutchinson’s sign indicates an 
increased risk of ocular involvement in herpes zoster 
ophthalmicus (HZO). We examined the sensitivity of 
Hutchinson’s sign as an indicator of ocular involvement in a 
consecutive series of patients presenting with HZO.
Methods. We conducted a descriptive observational 
prospective study of patients ≥18 years old presenting with 
HZO and consenting to pre- and post-test counselling and 
HIV and CD4 testing. A full ophthalmological examination 
focused on the extent of ocular involvement, and the presence 
of Hutchinson’s sign was confirmed by two clinicians.
Results. Thirty-three patients were enrolled; 29 were HIV 
positive, of whom 18 (62%) had not been diagnosed with HIV 
prior to enrolment. Of the 29 HIV-positive patients, 21 (72%) 
were Hutchinson’s sign positive (HSP), all of whom had 
intra-ocular involvement (95% confidence interval 88 - 100%). 
Of the 8 HIV-positive, Hutchinson’s sign-negative (HSN) 
patients, 4 did and 4 did not display intra-ocular involvement. 
Neither the mean CD4 count nor the average age in the HSP 
group differed significantly from the HSN group.
Conclusion. We confirmed that a Hutchinson’s sign- and HIV-
positive patient with HZO has a very high positive predictive 
value for intra-ocular involvement. Neither age nor CD4 
count had predictive value for ocular involvement. Young 
adults presenting with HZO should be suspected of having 
HIV, and HIV-positive patients with HZO but HSN may still 
have ocular involvement. All patients with HZO should be 
seen by an ophthalmologist.
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suggest that, in contrast to opportunistic infections such as 
cytomegalovirus that occur in profound immunodeficiency, 
HZO rather occurs in immunodysregulation.18
We aimed to evaluate the sensitivity of Hutchinson’s sign as 
a marker of ocular involvement in a series of consecutive HZO 
cases in a population at risk for HIV disease, and to explore 
the relationship between CD4 counts in the HIV-positive sub-
group with and without a positive Hutchinson’s sign.
Methods
We conducted a descriptive observational study of patients 
with HZO referred to the Division of Ophthalmology, 
Tygerberg Academic Hospital, Tygerberg, Western Cape, 
during 2007. The study was approved by the Ethics Committee 
of the Bioethics Unit, Stellenbosch University, Western Cape. 
Patients were included if they were ≥18 years old, able to 
give informed consent, and willing to undergo HIV and CD4 
serological testing, participate in the study and return for a 
follow-up visit. Age <18 and refusal to consent to HIV/CD4 
serological testing or refusal to participate, were exclusion 
factors.
Patients underwent a routine ophthalmic examination, 
specifically looking for the sequelae of HZO and its eye 
involvement. A second ophthalmologist confirmed the presence 
or absence of Hutchinson’s sign, to eliminate misdiagnosis.
After obtaining written consent and pre-counselling, HIV 
serology and CD4 counts were dispatched to the local National 
Health Services laboratory with standard protocols for 
confirmation.
All patients underwent HIV post-test counselling, and were 
referred for antiretroviral therapy where appropriate. Age, time 
since initial diagnosis of HIV, presence of HAART, and extent 
of ocular involvement were documented. Conjunctivitis alone 
was not regarded as representing intra-ocular involvement. 
All patients received standard oral antiherpetic treatment in 
accordance with departmental protocols and the extent of the 
disease.
Statistical analysis
Data were evaluated and statistically processed; a 95% 
confidence interval (CI) was calculated, using binomial 
distribution.
Results
Of the 33 patients enrolled, 29 were HIV positive, of whom 18 
(62%) were first diagnosed as HIV positive at the time of the 
study. Of the 11 patients previously known to be HIV positive, 
only 2 were on HAART on presentation (Table I).
Of the 29 HIV positive patients, 21 (72%) were Hutchinson’s 
sign positive (HSP). All 21 (100%) of these patients had intra-
ocular involvement (95% CI 88 - 100%). Of the 8 HIV-positive 
but Hutchinson’s sign-negative (HSN) patients, 4 had intra-
ocular involvement and 4 did not (50% for each sub-group).
Average CD4 count in the HSP sub-group was 290.6 (range 
38 - 772). This did not differ significantly from the HSN 
sub-group (289.4; range 91 - 897). The mean age of the HIV-
positive, HSP patients was 29.7 years (range 20 - 47), and 34.6 
years (range 24 - 46) for the HIV-positive, HSN cases (Table 
I). This difference was not statistically significant. Of the 21 
HIV-positive and HSP patients, 13 (62%) were female. Of the 
total group of 33 patients, 24 (73%) were black, 7 (21%) were 
coloured and 2 (5%) were white.
Discussion
The magnitude of the HIV pandemic makes it one of the most 
important health issues in sub-Saharan Africa. Although the 
HIV incidence in the Western Cape is one of the lowest in the 
country, it is still rising – 8.5% in 2001 compared with 15.4% in 
2006.19 According to the South African National HIV Survey of 
2005, 13.3% of females and 8.2% of males in South Africa over 
the age of 2 years were HIV-positive.19 It is imperative that 
patients with potentially vision-threatening ocular involvement 
are identified as early as possible and appropriately referred 
for specialised eye care. Delays in treatment and inadequate 
medical therapy for herpes zoster are associated with more 
severe ocular complications and visual loss in HZO disease.20 
Owing to the 6 - 15-fold increase in the incidence of HZO in 
HIV-positive patients compared with the general population, it 
can be presumed that HIV is the most common cause of VZV 
re-activation in the populations at risk.
Our findings confirm that a positive Hutchinson’s sign in 
an HIV-positive patient with HZO is a specific predictor of 
intra-ocular involvement. Intra-ocular involvement ranges 
from mild keratitis or anterior uveitis to blinding disease with 
corneal perforation. As timely intervention may decrease 
the complications of this disease, all such patients should be 
referred to an ophthalmologist for evaluation. This step should 
be one of the criteria for ophthalmic referral of patients by 
primary level health workers, who should be made more aware 
of the relevance of Hutchinson’s sign.
We did not find the CD4 count to be a significant 
predictor of ocular involvement, supporting previous 
findings and suggesting that HZO occurs in the setting of 
immunodysregulation rather than immunocompromise.7,13-16 
Further studies into immunological factors that can predict 
ocular involvement in HZO are awaited.
Our study confirms previous observations that HZO in 
young patients may be the presenting sign of HIV positivity, as 
62% of our patients with HZO were diagnosed for the first time 
as HIV positive at the time of HZO presentation. It confirms 
previous findings that HZO in a young, especially black 
African, patient is very suggestive of underlying retroviral 
disease.10
Table I. HIV-positive patients with HZO (N=29, 18 newly 
diagnosed)
     HSP  HSN
Number     21  8
Ocular involvement    21 (100%) 4 (50%)
Mean age (years) (range)   29.7 (20 - 47) 34.6 (24 - 46)
Male:female ratio    ≈2:3  ≈2:3
Mean CD4 count (range)   290.6 (38 - 772) 289.4 (91 - 987)
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There was no difference in average age between the group 
with ocular involvement and the group without, and no 
identifiable link between age and severity of disease. The 
higher incidence among females probably reflects the increased 
incidence of HIV in females in the broader population and is 
in keeping with the South African National HIV Survey 200519 
demographics.
As with all patients, HIV-positive patients with HZO and 
a negative Hutchinson’s sign may still develop intra-ocular 
involvement. Hutchinson’s sign therefore has a poor negative 
predictive value. All patients should be thoroughly examined 
for any signs of intra-ocular involvement.
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